

MATERIAL SAFETY DATA SHEET

FUROSEMIDE INJECTION / FUROSEMIDE SPECIAL INJECTION

CODE: L0010210 (2 mL) et L0010211 (4 mL) DIN: 02360365 CODE: L0010212 (25 mL) DIN: 02360446 (25 mL)

1 – IDENTIFICATION

Company: Omega Laboratories Limited

Manufactured by: 11177 Hamon st.

Montreal, Canada

H3M 3E4

Telephone: (514) 335-0310 **Fax:** (514) 339-1407 **Date Prepared:** 2015-09-08

2 - INGREDIENT

Hazardous Ingredients	CAS#	PEL	ILV	%
Furosemide	54-31-9	N/A	N/A	1
Other Ingredients				
Sodium Hydroxide	1310-73-2	2 mg/m^3	2 mg/m^3	
Water for injection	7732-18-5	N/A	N/A	q.s.

3 - PHYSICAL DATA

Boiling Point: 100°C, 212°F **Specific Gravity**: ~ 1.0

Vapor Pressure (mm Hg/20°C): 17.5 Vapor Density (air = 1): N/A Evaporation Rate: N/A Solubility in Water: Soluble.

pH: 8.0 - 9.3

Appearance: Clear, colorless and odorless liquid.

4 - FIRE AND EXPLOSION HAZARD DATA

Flash Point (and method): N/A Flammability: Non-flammable

Extinguishing Media: Use extinguishing media appropriate for primary

cause of fire

Special Fire Fighting Procedures: No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing

and self contained breathing apparatus.

Sensitivity to static discharge & Explosive power: None.

5 - REACTIVITY DATA

Stability: Stable.

Incompatibility (material to avoid): Acids. **Conditions to Avoid:** Protect from light.

Hazardous decomposition products: Toxic fumes of chlorine, sulfur and

nitrogen oxides.

Hazardous Polymerization: Will not occur.

6 - HEALTH HAZARD ASSESSMENT

Emergency Overview: In clinical use, this material is used to promote urination. Possible target organs include the kidneys, fetus, DNA and ears. Occupational Exposure Potential: Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms: No signs or symptoms from occupational exposure are known. Clinical data suggest the following: electrolyte imbalances, dry mouth, weakness, lethargy, drowsiness, restlessness, muscle pain, muscle weakness, decreased blood pressure, fast heart rate, nausea, vomiting, ringing in the ear, dizziness, headaches.

Medical Conditions Aggravated by Exposure: Hypersensitivity to the material and/or similar materials. Pre-existing ailments in the following organs: kidney, ears, liver.

7 - EMERGENCY PROCEDURES

Skin: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention.

Eyes: Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Treatment: Provide symptomatic / supportive care as necessary.

8 - TOXICOLOGIC INFORMATION

9 - PRECAUTIONS INFORMATION

Steps to be taken in case material is released or spilled: Absorb with suitable material and clean affected area with soap and water.

Waste Disposal Method: Dispose of materials according to the applicable federal, state, or local regulations

Precautions to be taken in Handling and Storing: For product protection store at controlled room temperature of 15-30°C. Protect from freezing, light and extreme heat.

10 - CONTROL MEASURES

Respiratory Protection: Respiratory protection is not needed during normal product use.

Skin Protection: If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.

Eye Protection: Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.

Engineering Controls: Engineering controls are not needed during normal product use conditions.

11 - TRANSPORTATION INFORMATION

Not DOT Regulated